SEPTERNA INC

Insider buying by Septerna’s Senior VP signals strong confidence in its Phase II GPCR pain drug, SEP‑101, and a bullish outlook for the biotech’s rising share price.

Insightful insider buying at Septerna Inc. shows long‑term confidence: low‑cost option exercise, strategic sales, and a bullish net purchase of 333 shares. Discover why investors should watch this biotech’s pipeline.

Daniel Long’s insider trades reveal a mix of strategic buying and high‑price selling, signaling confidence in Septerna’s drug‑discovery pipeline and hinting at possible upcoming liquidity events.